Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults

Journal of Clinical Psychopharmacology

Volumn 25, Issue 1, 2005, Pages 19-25

  Janowsky, David S ^a,b,d   Barnhill, L Jarrett ^a,b   Shetty, Mahesh ^a   Davis, John M ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Murdoch Center   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; BENZATROPINE; CARBAMAZEPINE; CHLORPROMAZINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; LOXAPINE; NEUROLEPTIC AGENT; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRIHEXYPHENIDYL; VALPROIC ACID;

ADULT; AGED; AGGRESSION; AUTOMUTILATION; BEHAVIOR CONTROL; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; LOW DRUG DOSE; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; REVIEW;

ADULT; AGED; AGGRESSION; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MENTAL RETARDATION; MIDDLE AGED; RECURRENCE; SELF-INJURIOUS BEHAVIOR;

EID: 12344307841     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000150218.51433.7b     Document Type: Review

References (22)

1. Cohen S, Underwood MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry. 1994;55:440-444.
2. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psych. 2003;42(6):622-623.
3. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psych. 1997;36: 685-693.
4. Janowsky DS, Barnhill J, Davis JM. Olanzapine treatment of self-injurious, aggressive and disruptive behavior in institutionalized adults with intellectual disability. J Clin Psychiatry. 2003;64(10):1258-1265.
5. Williams H, Clarke R, Bouras N, et al. Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability. J Intellect Disabil Res. 2000;44:164-169.
6. Baumeister AA, Sevin JA, King BH. Neuroleptics. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University Nisonger Center, Columbus, Ohio; 1998:133-149.
7. Aman MG, White A. Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents. J Autism Dev Disord. 1988;18(3):355-366.
8. Kalachnik JE, Leventhal BB, James DH, et al. Guidelines for the use of psychotropic medication. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State Nisonger Center, Columbus, Ohio; 1998:45-72.
9. May P, London EB, Zimmerman T, et al. A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann Clin Psychiatry. 1995; 7(4):155-160.
10. Wressell SE, Tyrer SP, Berney TP. Reduction in antipsychotic drug dosage in mentally handicapped patients: a hospital study. Br J Psychiatry. 1990;157:101-106.
11. Singh NN, Aman MG. Effects of thioridazine dosage on the behavior of severely mentally retarded persons. Am J Ment Defic. 1981;85:580-587.
12. Aman MG, Teehan CJ, White AJ, et al. Haloperidol treatment with chronically medicated residents: dose effects on clinical behavior and reinforcement contingencies. Am J Ment Retard. 1989;93:452-460.
13. Schatzberg AF, Cole JO, DeBattista C. Manual of Clinical Psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Press; 1997.
14. Baldessarini RJ, Davis JM. What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res. 1980;3(2):115-122.
15. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002;159(4):554-560.
16. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry. 1993;54:24-30.
17. McEvoy JP. The neuroleptic threshold as a marker of minimum effective neuroleptic dose. J Clin Psychiatry. 1986;47(suppl):30-33.
18. McEvoy JP, Hogarty GE, Steingard S. Optional dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48(8):739-745.
19. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:1-17.
20. Rao JM, Cowie VA, Mathew B. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects. Acta Psychiatr Scand. 1987; 76(5):507-513.
21. Chouinard G, Jones B, Remington G. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13(1):149.
22. Jin H, Meyer JM, Jeste D. Phenomenology of and risk factors for new onset diabetes and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.